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Abstract
Introduction: Women with polycystic ovary syndrome (PCOS) often suffer from obesity and insulin resistance. The role of proinsulin, 
which is known to be an indicator of fertility outcomes in PCOS women, and that of adiponectin, in the pathogenesis of PCOS is not 
well elucidated. Our objective was to determine proinsulin, adiponectin, hsCRP and other hormonal and metabolic parameters in PCOS 
women before and after metformin treatment.
Material and methods: Two PCOS groups of patients of reproductive age (90 lean and 88 obese or overweight) with two control groups, 
adjusted for body mass index (BMI), were compared at baseline. 32 PCOS women were studied at baseline, after three and six months of 
metformin (1,000 mg/day) treatment. Clinical, anthropometric, biochemical and hormonal parameters were assessed. 
Results: Proinsulin and hsCRP levels were the highest in obese PCOS women and were statistically different than in lean PCOS women 
(proinsulin: 11.4 v. 6.9 pmol/L; hsCRP 2.46 v. 0.47 mg/L, p < 0.01) and than in obese controls. Levels of adiponectin were dependant on 
BMI. Plasma proinsulin and androstenedione levels decreased after metformin treatment only in obese PCOS women.
Conclusions: PCOS, when accompanied by obesity, is associated with elevated proinsulin concentrations, which correlates with higher 
hsCRP and increased FAI. Proinsulin level decreases due to metformin treatment. Our results suggest that obese or overweight PCOS 
and lean PCOS are characterised by different hormonal and metabolic parameters and have a different response to metformin treatment. 
(Endokrynol Pol 2014; 65 (1): 2–10)
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Streszczenie
Wstęp: Zespół policystycznych jajników (PCOS) często wiąże się ze współwystępowaniem otyłości i insulinooporności. Rola proinsuliny, 
której stężenie koreluje z płodnością w PCOS, oraz adiponektyny nie jest określona w patogenezie PCOS. Celem pracy było zbadanie stężeń 
proinsuliny, adiponektyny, hsCRP i innych hormonalnych i metabolicznych parametrów u kobiet z PCOS przed i po leczeniu metforminą.
Materiał i metody: Porównano 2 grupy kobiet w wieku rozrodczym z PCOS (90 z prawidłową masą ciała i 88 z nadwagą lub otyłością) 
z 2 grupami kontrolnymi dobranymi pod względem wskaźnika masy ciała (BMI). Trzydzieści dwie kobiety z PCOS, u których wdrożono 
leczenie metforminą w dawce 1000 mg/d, były zbadane w warunkach podstawowych, po 3 oraz 6 miesiącach leczenia. Oceniano para-
metry kliniczne, antropometryczne, biochemiczne i hormonalne.
Wyniki: Otyłe kobiety z PCOS charakteryzowały się najwyższymi stężeniami proinsuliny i hsCRP , które były statystycznie istotnie wyższe 
w porównaniu ze szczupłymi kobietami z PCOS (proinsulina: 11,4 v. 6,9 pmol/l; hsCRP 2,46 v. 0,47 mg/l, p < 0,01) i z otyłymi kobietami 
z grupy kontrolnej. Stężenia adiponektyny były zależne od BMI. Stosowanie metforminy spowodowało obniżenie stężeń proinsuliny 
i androstendionu tylko w grupie otyłych kobiet z PCOS.
Wnioski: Zespół PCOS przebiegający z nadwagą lub otyłością wiąże się ze zwiększonym stężeniem proinsuliny, które koreluje z pod-
wyższonym hsCRP i zwiększonym wskaźnikiem FAI. Stężenie proinsuliny ulega obniżeniu podczas leczenia metforminą. Uzyskane 
wyniki sugerują, że kobiety szczupłe i otyłe z PCOS charakteryzują się różnymi parametrami hormonalnymi i metabolicznymi oraz różną 
odpowiedzią na działanie metforminy. (Endokrynol Pol 2014; 65 (1): 2–10)
Słowa kluczowe: PCOS; proinsulina; insulinooporność; adiponektyna; białko C-reaktywne; otyłość
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Introduction
Polycystic ovary syndrome (PCOS) is a heterogeneous 
condition affecting 5–10% of women of reproductive 
age [1]. Regardless of the diagnostic criteria used, 
many different phenotypes of PCOS may be identified. 
Despite the strong relationship of PCOS and obesity, 
insulin resistance, diabetes, chronic inflammation and 
other metabolic disturbances, neither elevated insulin 
resistance indices nor body mass index (BMI) are criteria 
for recognising PCOS. The pathogenesis of PCOS is still 
unknown. Many factors including genetics, intrauterine 
or environmental ones play a significant role. 
There are two paths which could be taken in order 
to attempt an explanation of hormonal disturbances 
and etiology of PCOS: insulin resistance, hyperinsuli-
naemia and defects in insulin action on the one hand, 
and disturbances in gonadotropin action on the other. 
Women with PCOS have a much higher risk of type 
2 diabetes and metabolic syndrome [2, 3]. The American 
Diabetes Association treats PCOS as a risk factor for type 2 
diabetes mellitus (T2DM) and recommends screening [4]. 
Looking for factors which could play a role in the 
pathogenesis of PCOS, especially when it is accom-
panied by obesity, we concentrate on proinsulin and 
adiponectin. High-sensitive C-reactive protein (hsCRP), 
as a marker of chronic inflammation in PCOS, could 
also be elevated.
Proinsulin, which is an insulin precursor produced 
in the pancreas, can be a marker of insulin resistance 
or beta-cell dysfunction [5, 6] and is suspected to be 
involved in the pathogenesis of macroangiopathy. 
Proinsulin concentration is an independent indicator of 
future type 2 diabetes development. It has been found 
that in diabetic patients proinsulin level correlates with 
insulin resistance better than homeostasis model assess-
ment (HOMA) [7]. How the proinsulin level correlates 
with fertility in PCOS patients is still unclear, but, as 
Rausch et al. revealed [8] proinsulin, but not insulin 
concentration, correlates with ovulation, pregnancy 
rate and live birth. Higher proinsulin levels have been 
determined in women who have never been pregnant 
vs. fertile women [9]. 
Adiponectin is an adipocytokine produced in white 
adipose tissue (especially visceral fat tissue), but its 
concentration is reduced in obesity. The adiponectin 
level correlates negatively with insulin resistance, and 
hypoadiponectinaemia is also associated with T2DM, 
obesity, atherosclerosis and coronary vascular diseases 
(CVD). Thus adiponectin could be treated as a potential 
factor involved in the pathogenesis of PCOS.
Using available criteria for PCOS such as the Rot-
terdam or The Androgen Excess Society (AES) criteria, 
we can recognise many different phenotypes of PCOS 
[10–12]. Neither obesity nor insulin resistance are essen-
tial for a diagnosis of PCOS, but due to epidemiological 
data and suggestions of experts of AES, at least one of 
them should be crucial for the final diagnosis of PCOS.
In the present study, we investigated proinsulin, 
adiponectin and hsCRP levels in PCOS patients vs. 
controls, but normal or increased BMI was a criterion 
for assigning a subject to one of the examined groups. 
Many other hormonal and metabolic factors were de-
termined, too. In the second part of the study, PCOS 
women were treated with a small dose of metformin 
(500 mg two times daily) for six months. We investigated 
the influence of metformin treatment on proinsulin, 
adiponectin, hsCRP and on clinical outcomes and 
hormonal parameters like androgen levels in the whole 
group of PCOS participants and within two subgroups: 
lean and overweight/obese PCOS patients.
Material and methods
Subjects
We investigated 178 PCOS women (aged 16–40 years): 
90 lean (BMI < 25 kg/m2) and 88 overweight or obese 
(BMI ≥ 25 kg/m2) and 42 (aged 17–40) healthy women 
(31 with BMI < 25 kg/m2 and 11 with BMI ≥ 25 kg/ m2). 
A diagnosis of PCOS was made according to the Rotter-
dam criteria [13]. All women in the control groups were 
in good general health, had regular menstruations, no 
sign of hyperandrogenism and normal-appearing ova-
ries in ultrasonography. They had not used any drugs 
chronically, including oral contraceptive pills (OCP).
All subjects were classified into one of four groups:
 — Group 1 — lean PCOS (BMI < 25 kg/m2);
 — Group 2 — obese or overweight PCOS (BMI ≥ 
25 kg/m2);
 — Group 3 — lean controls (BMI < 25 kg/m2);
 — Group 4 — obese or overweight controls (BMI ≥ 
25 kg/m2).
In the second part of the study, 32 PCOS women 
(N = 16 with BMI < 25 kg/m2 and N = 16 with BMI 
≥ 25 kg/m2) were treated with metformin in a dose of 
1,000 mg daily. Clinical, hormonal and biochemical 
assessment was performed at baseline and after three 
and six months of treatment. In none of the 32 patients 
were impaired fasting glucose (IFG), impaired glucose 
tolerance (IGT) or T2DM diagnosed at baseline. The 
full observational period was finished by 28 patients. 
All the participants gave their informed consent be-
fore the study, which was approved by the institutional 
ethics committee.
Protocol
All subjects underwent a physical examination which 
included anthropometric measurements and detailed 
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past and present medical history including drugs, men-
strual history and fertility. BMI was calculated. 
All hormonal and biochemical measurements were 
performed in the follicular phase of spontaneous or 
progestin-induced menstrual cycle.
Measurements
After an overnight fast, basal levels of proinsulin, 
adiponectin, hsCRP, sex hormone binding globulin 
(SHBG), estradiol (E2), testosterone, androstenedione, 
and DHEA-S were determined. Free androgen index 
(FAI) and free testosterone (fT) were calculated as 
previously described [14, 15]. All subjects underwent 
an oral glucose tolerance test (OGTT) with a load 
of 75 g glucose; glucose and insulin at 0, 30, 60 and 
120 min. were determined, and insulin resistance 
indices (HOMA, Quicki, Matsuda, SigmaIRI and area 
under the curve (AUC) for glucose and insulin) were 
calculated as previously described.
Assays
Proinsulin was determined by radioimmunoassay (RIA) 
kit, LINCO Res. (sensitivity — 2 pmol/L, range: 2–100 
pmol/L, specifity — human proinsulin = 100%, human 
insulin < 0.1%, C-peptide < 0.1%) and adiponectin by 
RIA kit, LINCO Res. (sensitivity — 1ng/mL, specifity 
— human adiponectin = 100%, human C1q < 0.01%). 
Insulin levels were determined by BI-INSULIN 
IRMA, CIS Bio International; (sensitivity — 0.2 mIU/mL, 
range: 0.2–500 mIU/mL, specifity — human proinsulin 
< 0.0001%, C-peptide < 0.003).
Plasma glucose concentrations were determined by 
an oxydase method (Integra 400);
HsCRP was measured using the immunoturbidi-
metric method (Integra 400).
Levels of serum total testosterone, androstenedione 
and DHEA-S were quantified by RIA (TESTO-CT2 
Kit - CIS Bio International, France; Androstendione 
RIA DSL-3800, Diagnostic Products Corporation, USA, 
Spectria DHEAS RIA kit - Orion Diagnostica, Finland, 
respectively). 
SHBG was determined by immunoradiometric as-
say (IRMA) method (Spectra SHBG IRMA test — Orion 
Diagnostica), estradiol by an automated chemilumi-
nescence system (Immulite 2000; Diagnostic Products 
Corporation, USA).
Statistical analysis
Values are reported as mean ± SD and as a median in 
the brackets. Normality of distribution was assessed by 
Shapiro-Wilk test. Because of the absence of normal-
ity, nonparametric testing: U-Mann Whitney, ANOVA 
Kruskal-Wallis, ANOVA Friedmann were used. Spear-
man rank correlation was used to evaluate the relation-
ship between analyzed data. For statistical analysis 
Statistica 5.1 PL and 9.0 PL programmes were used. 
The limit of statistical significance was set at P < 0.05. 
Results
Clinical, hormonal and metabolic  
parameters at baseline
Baseline characteristics of all groups are presented in 
Table IA, B and C.
The ‘obese PCOS’ group was characterised by higher 
insulin resistance. There were statistically significant dif-
ferences in all checked insulin-resistance indices between 
‘obese PCOS’ and ‘lean PCOS’. ‘Obese PCOS’ and ‘obese 
Controls’ differed in most insulin-resistance indices, too.
Hs-CRP levels were the highest in the group of ‘obese 
PCOS’; there was statistically significant difference be-
tween this group vs. ‘obese Controls’ (2.46 v. 0.88 mg/L; 
p < 0.05) and v. ‘lean PCOS’ (2.46 v. 0.47 mg/L; p < 0.05), 
however there were no differences between ‘lean 
PCOS’ v. ‘lean Controls’ and ‘lean Controls’ v. ‘obese 
Controls’. Data is presented in Table IC and Figure 1.
Proinsulin and adiponectin levels at baseline
Proinsulin concentrations were statistically different 
and the highest in the group of ‘obese PCOS’ women 
compared to ‘lean PCOS’ women (Me = 11.4 pM/L v. 
6.95, p < 0.001) and to ‘obese Controls’ (Me = 11.4 pM/L 
v. 7.7, p < 0.05). There were no differences between 
‘obese Controls’ vs. ‘lean Controls’ and ‘lean PCOS’ v. 
‘lean Controls’. Data is presented in Table II and Figure 2. 
Adiponectin concentrations differed between ‘lean 
PCOS’ v. ‘obese PCOS’ and ‘lean Controls’ v. ‘obese 
Controls’; no other differences were found. Data is 
shown in Table II.
Correlations
Proinsulin concentrations were positively correlated 
with FAI (r = 0.23, p < 0.05) and hsCRP (r = 0.4, p < 0.05) 
only in the group of obese PCOS women. Data is shown 
in Table III.
Metformin treatment
Baseline characteristics of the group of 32 PCOS women 
who were treated with metformin are presented in 
Table IVA and Figure 3 (M1). In the whole group dur-
ing the six-month period of treatment we observed 
statistically significant decrease in body mass, BMI, an-
drostenedione and proinsulin levels (Table IVA, Fig. 3); 
there was no influence on adiponectin concentration. 
We did not observe any changes in other checked pa-
rameters (data not shown).
All determined parameters were checked in sub-
groups — lean and obese PCOS. This analysis revealed 
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Table I. Comparison between four groups: A. clinical characteristics, B. hormonal characteristics, C. metabolic characteristics
Tabela I. Porównanie w czterech badanych grupach: A. charakterystyka kliniczna; B. badania hormonalne; C. badania 
metaboliczne
A. Clinical characteristics
Group 1
Lean PCOS
Group 2
Obese PCOS
p Group 3
Lean Controls
Group 4
Obese Controls
p
Body mass [kg] 58,37 ± 6.14 
[58] a
86.34 ± 18.1 
[82.5] a
< 0.01 56.02 ± 6.91 
[56.5] a
78.88 ± 18.37 
[67.4] a
 < 0.01
BMI 21.03 ± 1.83
[21.05] a
31.69 ± 5.81
[30.36] a
 < 0.01 20.76 ± 2.09
[20.24] a
29.38 ± 5.99
[25.85] a
< 0.01
WHR 0.74 ± 0.04 
[0.74] a
0.85 ± 0.1 
[0.82] a
< 0.01 0.73 ± 0.04 
[0.73] a
0.8 ± 0.04 
[0.79] a
< 0.01
B. Hormonal characteristics
Group 1
Lean PCOS
Group 2 p Group 3 Group 4 p
Ob. PCOS Lean Controls Ob.Controls
Testosterone [ng/mL] 0.75 ± 0.3 
[0.7] c
0.83 ± 0.35 
[0.8] b
NS 0.55 ± 0.2 
[0.6] c
0.56 ± 0.2 
[0.6] b
NS
Androstenedione [ng/dL] 355 ± 121 
[331] c
376 ± 163 
[366] b
NS 230 ± 77 
[225] c
265 ± 97 
[275] b
NS
DHEA-S [ng/mL] 3.167 ± 1.191
[3.004] c
3.347 ± 1.432
[3.022] a
NS 2.185 ± 772
[2.038] c
2/.634 ± 784
[2.552] a
NS
SHBG [nmol/L] 56.01 ± 22.82 
[53] a
31.77 ± 18.61 
[27] a
< 0.01 64.44 ± 24.33 
[60] a
42.03 ± 21.97 
[35.3] a
< 0.05
FAI 5.3 ± 2.8 
[4.5] c
11.1 ± 7.2 
[8.8] b
 < 0.01 3.1 ± 1.2 
[4.0] c
4.8 ± 2.2 
[5.1] b
< 0.05
fT [pmol/L] 33.94 ± 13.84 
[31.85] c
44.64 ± 17.17 
[41.77] b
< 0.001 22.87 ± 8.87 
[21.45) c
28.73 ± 11.35 
[23.68] b
NS
E2 [pg/mL] 52.06 ± 38.14 
[41.15] c
52.46 ± 25.55 
[47.00] a
NS 69.30 ± 42.30 
[56.90] c
49.70 ± 16 
[46.35] a
NS 
C. Metabolic characteristics
Group 1 Group 2 p Group 3 Group 4 p
Lean PCOS Obese PCOS Lean Controls Obese Controls
Fasting glucose [mg/dL] 83.52 ± 7.18 
[83.40] a
87.23 ± 7.55 
[87.00] a
 < 0.01 82.78 ± 6.69 
[82.00] a
85.46 ± 9.38 
[85.00] a
NS
Fasting insulin [mIU/mL] 5.26 ± 2.85 
[5] a
11.69 ± 6.75 
[10] b
< 0.01 4.70 ± 1.58 
[5] a
5.50 ± 2.27 
[4,5] b
NS
HOMA 1.21 ± 0.9 
[0.98] a
2.54 ± 1.53 
[2.2] b
< 0.01 1.02 ± 0.46 
[0.97] a
1.46 ± 1.01 
[1.09] b
NS
Quicki 0.387 ± 0.038 
[0.385] a
0.345 ± 0.037 
[0.339] b
< 0.01 0.389 ± 0.027 
[0.39] a
0.374 ± 0.034 
[0.38 ] b
NS
AUC glucose 12.941 ± 2.422 
[12.972] c
14.208 ± 2.642 
[14.001] a
< 0.01 11.718 ± 2.243 
[11.507] c
13.959 ± 3.627 
[14.010] a
NS
AUC insulin 4.177 ± 2.284 
[3.495] c
7.934 ± 4.787 
[7.125] b
< 0.01 2.774 ± 1.014 
[2.520] c
3.171 ± 1.122 
[2.580] b
NS
Sigma IRI 118 ± 59 
[100] c
230 ± 135 
[211] b
< 0.01 81 ± 28 
[74] c
129 ± 111 
[86] b
NS
Matsuda index 10.71 ± 5.97 
[9.83] c
5.64 ± 3.79 
[4.26] b
< 0.01 12.39 ± 3.93 
[12.19] c
9.12 ± 5.04 
[10.41] b
NS
hsCRP [mg/L] 0.78 ± 0.69 a 
[0.47]
3,70 ± 3,77 b 
[2.46]
< 0.05 0.83 ± 0.68 a 
[0.56]
1.33 ± 1.16 b 
[0.88]
NS
a — p > 0.05 when comparing group 1 v. group 3 and group 2 v. group 4; b — significant difference between group 2 and group 4, p < 0.05; c — significant 
difference between group 1 and group 3, p < 0.05 
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Figure 1. High sensitive C-reactive protein (hsCRP) values. Comparison between four subgroups.  — median
Rycina 1. Stężenia hsCRP w 4 podgrupach.  — mediany
Table II. Proinsulin and adiponectin levels in four groups
Tabela II. Stężenia proinsuliny i adiponektyny w czterech badanych grupach
Group 1
Lean PCOS
Group 2
Obese PCOS
p Group 3
Lean Controls
Group 4
Obese Controls
p
Proinsulin [pmol/L] 7.67 ± 3.47  
[6.9] a
12.9 ± 7.23  
[11.4] b
 < 0.01 6.85 ± 2.65  
[6.6] a
8.21 ± 2.86  
[7.7] b
NS
Adiponectin [mg/mL] 12.13 ± 4.21  
[11.5] a
9.52 ± 4.44  
[8.3] a
 < 0.01 13.30 ± 4.8  
[12.1] a
9.52 ± 3.94  
[10.4] a
0.06
a — p > 0.05 when comparing group 1 v. group 3 and group 2 v. group 4; b — significant difference between group 2 and group 4, p < 0.05; c — significant 
difference between group 1 and group 3, p < 0.05
Figure 2. Proinsulin concentrations. Comparison between four groups.  — median
Rycina 2. Stężenia proinsuliny w 4 podgrupach.  — mediany
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that the statistically significant decrease in the whole 
group was due to changes in the ‘obese PCOS’ group 
(Table IVB), whereas changes in ‘lean PCOS’ were not 
statistically significant. Figure 4 shows these findings 
for proinsulin concentrations. Similar results were 
found for body mass, BMI and androstenedione con-
centration.
Discussion
These results demonstrate that women with PCOS and 
excess body fat are characterised by different hormonal 
and metabolic parameters, including the highest proin-
sulin levels, compared to both lean PCOS patients and 
obese controls. Moreover, exclusively in this group cor-
relations between proinsulin and hsCRP and proinsulin 
and FAI are observed and metformin causes significant 
decreases in proinsulin and androstenedione levels 
solely in obese/overweight PCOS patients.
It has been noted repeatedly that PCOS per se is an 
independent risk factor of insulin resistance [16–18] 
and that obese PCOS women have different metabolic 
and hormonal parameters than lean PCOS patients 
[19]. Pasquali et al. demonstrated [20] that obese PCOS 
women are characterised by worse insulin resistance 
than lean PCOS patients. As much as 30-70% of PCOS 
women are overweight or obese [21–23]. Therefore 
comparing this population to a healthy control group, 
without adjusting for BMI, could be misleading. 
Our study confirmed different metabolic and hor-
monal profiles in PCOS women with increased BMI 
vs. lean PCOS patients. This could suggest that there 
is a different pathogenesis of this syndrome in patients 
with different phenotypes. The AES criteria [11] point 
clinical or biochemical hyperandrogenism as a sine qua 
non condition for the diagnosis of PCOS; the problem 
of many different phenotypes of PCOS could also be 
connected to the presence of obesity and/or insulin 
resistance.
The group of overweight/obese PCOS women 
was characterised by worse insulin resistance and the 
highest and statistically different concentrations of 
proinsulin, FAI, free testosterone and hsCRP than those 
in a group of lean PCOS and in obese controls. Corre-
lations between these factors existing only in a group 
of overweight/obese PCOS, and the above-mentioned 
Table III. Correlations within lean and obese PCOS groups
Tabela III. Korelacje w grupie szczupłych i otyłych kobiet z PCOS
Proinsulin [pmol/L] Lean PCOS (group 1) Obese PCOS (group 2)
r p r p
hsCRP [mg/L] –0.052530 NS 0.417037  < 0.05
Androstenedione [ng/dL] 0.000287 NS –0.034978 NS
Testosterone [ng/mL] 0.212666 NS –0.053709 NS
FAI 0.122670 NS 0.229280  < 0.05
Figure 3. The influence of metformin treatment in a group of 32 PCOS women on proinsulin concentration. M1 — baseline, 
M3 — 3 month treatment period, M6 — 6 month treatment period. Data are presented as medians and quartiles, p < 0.01
Rycina 3. Wpływ leczenia metforminą na stężenia proinsuliny w grupie 32 osób z PCOS. M1 — wyjściowo, M3 — po 3 miesiącach 
leczenia, M6 — po 6 miesiącach leczenia. Dane przedstawiono jako mediany i kwartyle, p < 0,01
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Table IV. The influence of metformin treatment in PCOS women on selected parameters. A. The influence of metformin treatment 
in a group of 32 PCOS women on selected parameters; B. The influence of metformin treatment in a group of ‘obese PCOS’ 
women on selected parameters. M1 — baseline, M3 — 3 month treatment period, M6 — 6 month treatment period
Tabela IV. Wpływ leczenia metforminą kobiet z PCOS na wybrane parametry. A. Wpływ leczenia metforminą na wybrane 
parametry w grupie 32 osób z PCOS; B. Wpływ leczenia metforminą na wybrane parametry w grupie osób z PCOS z nadwagą/
otyłych. M1 — wyjściowo, M3 — po 3 miesiącach leczenia, M6 — po 6 miesiącach leczenia
A. The influence of metformin treatment in a group of 32 PCOS women on selected parameters
M1 M3 M6 p
Body mass [kg] 71.33 ± 15.34 
[67]
69.78 ± 14.33 
[68.7]
69.43 ± 13.93 
[67]
P < 0.05
BMI [kg/m2] 26.26 ± 5.95 
[24.20]
25.67 ± 5.54 
[23.90]
25.54 ± 5.43 
[23.91]
P < 0.05
Proinsulin [pmol/L] 10.0 ± 4.1 
[9.0]
7.5 ± 3.8 
[7.0]
7.4 ± 4.0 
[6,6]
P < 0.001
Androstenedione [ng/dL] 380 ± 133 
[375]
326 ± 131 
[286]
279 ± 117 
[237]
p < 0.05
Adiponectin [mg/mL] 9.68 ± 3.59 
[8.6]
9.92 ± 3.31 
[9.5]
9.51 ± 2.68 
[9.1]
NS
B. The influence of metformin treatment in a group of ‘obese PCOS’ women on selected parameters
M1 M3 M6 p
Body mass [kg] 87.5 ± 14.58 
[82.5]
85 ± 13.54 
[82.8]
84.2 ± 13.38 
[81.8]
 < 0.05
BMI [kg/m2] 31.19 ± 4.44 
[30.52] 
30.29 ± 4.06 
[29.5]
30.02 ± 4.00 
[29.57]
< 0.05
Proinsulin [pmol/L] 11.73 ± 4 
[10.5]
8.55 ± 4 
[8]
7.94 ± 3.2 
[7,7]
 < 0.05
Androstenedione [ng/dL] 387 ± 151 
[358]
288 ± 120 
[263]
268 ± 122 
[233]
< 0.05
Adiponectin [mg/mL] 8.52 ± 2.8 
[7.6]
8.63 ± 2.4 
[8.2]
8.40 ± 2.0| 
[8.4]
NS
Figure 4. The influence of metformin treatment in subgroups of lean and obese PCOS women on proinsulin.  M1 — baseline, M3 — 3 
month treatment period, M6 — 6 month treatment period.Data presented as means ± SD, * p < 0.05 ** p > 0.05 (NS)
Rycina 4. Wpływ leczenia metforminą na stężenia proinsuliny w podgrupie „PCO szczupłe’ i „PCO otyłe’. M1 — wyjściowo, M3 — 
po 3 miesiącach leczenia, M6 — po 6 miesiącach leczenia. Dane przedstawiono jako średnie ± SD. *p < 0.05, **p > 0.05 (NS)
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differences, suggest that we should consider two dif-
ferent phenotypes of PCOS:
 — phenotype with normal BMI,
 — phenotype with increased BMI.
Proinsulin concentration seems to be not only 
a marker of insulin resistance, but also a factor directly 
involved in the development of metabolic and hor-
monal disturbances in PCOS in the phenotype with 
increased BMI. Proinsulin could also play a role in the 
fertility in PCOS, as revealed in the study of Rausch et 
al.: “We were surprised to find proinsulin as a marker 
of success in ovulation, conception, pregnancy, and live 
birth in PCOS women” [8].
Levels of adiponectin in obese or overweight PCOS 
patients did not differ in obese or overweight healthy 
women, nor in lean PCOS v. lean controls. It seems 
that adiponectin level was related rather to fat mass 
accumulation than to PCOS per se.
C-reactive protein is treated as a marker of early ath-
erosclerosis. It is also an independent, sensitive marker 
of risk of CVD [3, 24, 25]. In our study obese/overweight 
PCOS women were characterised by the highest hsCRP 
concentrations and there were no differences in hsCRP 
levels between lean and obese controls and lean PCOS 
vs. lean controls. These differences between groups 
were analogous to those in proinsulin concentrations. 
In obese PCOS there was a correlation between hsCRP 
and proinsulin; such a correlation was not observed in 
lean PCOS women.
It is recommended to measure free testosterone 
or calculate it [15] in the process of establishing the 
diagnosis of PCOS. In our work there were statistically 
significant differences in the level of fT between groups, 
the highest value being determined in ‘obese PCOS’. 
The concentration of androstenedione, the position 
of which in the diagnosis of PCOS is still not well es-
tablished, seems to be a sensitive, well differentiating 
androgen, which could be helpful in the diagnosis of 
hyperandrogenaemia. Androstenedione was the only 
androgen which decreased due to metformin treatment 
only in ‘obese PCOS’.
Low dose of metformin resulted in a statistically 
significant decrease in proinsulin concentration after 
only three months of treatment and persisted during 
the next three months. The very important observation 
is that such an effect in the PCOS group was dependant 
on the decrease in ‘obese PCOS’. It is known [26] that 
obese PCOS women could benefit from pretreatment 
with metformin in ovulation induction. It has been 
shown that the lower the proinsulin concentration be-
fore pregnancy in PCOS women, the higher the chance 
of delivering a live birth [8]. Adiponectin concentration 
has not changed due to metformin treatment, although 
there was a decrease in body mass and BMI. In some 
previous studies [27, 28], the authors observed decrease 
in adiponectin, but the examined population of PCOS 
was characterised by very high BMI (mean 35 kg/m2 and 
43 kg/m2, respectively) so the effect could be secondary 
to the significant body mass reduction. In our study 
we have not observed decrease in hsCRP concentra-
tion. Previous studies have shown such an effect of 
metformin, especially in obese PCOS women [29]. Our 
results could be due to the relatively short observation 
period or the low dose of metformin, whereas it was 
sufficient to cause proinsulin decrease because of more 
direct influence. 
Metformin treatment in metabolically high risk 
patients with PCOS seems to be also beneficial because 
of the known influence of metformin on AMP-kinase 
(AMPK) and its potential antiatherogenic, antineoplas-
matic and life-prolonging action, via target of rapami-
cine (TOR) mechanism [30–33].
The advantage of our study is a number of included 
patients and the comparison of four groups, which 
eliminates the possible influence of excess body mass, 
not PCOS itself, on investigated parameters. It has 
revealed that hyperproinsulinaemia is dependent on 
coexistence of PCOS and obesity, but adiponectin con-
centration is rather due to body mass. 
To the best of our knowledge, what is new in this 
study is the recognition of a relationship between proin-
sulin concentration and hsCRP and FAI solely in obese 
PCOS patients and, finally, a decrease in proinsulin 
and androstenedione concentration after metformin 
treatment. 
This study has some notable limitations. Firstly, there 
was a disproportion between PCOS and control groups. 
It was determined by the small number of healthy 
young women without any menstrual disturbances nor 
hyperandrogenic signs who wouldn’t take any medi-
cines, including OCP. Secondly, PCOS was diagnosed 
according to the Rotterdam Criteria, which have some 
widely known limitations and generate many different 
phenotypes of PCOS. 
Conclusions
PCOS in obese women is associated with hyperproin-
sulinaemia, hyperandrogenaemia and increased hsCRP 
level, which correlate with each other. 
Proinsulin seems to be a sensitive marker of insulin 
resistance in PCOS women. 
The practical conclusion which can be drawn from 
this study is that in all PCOS patients both body fat 
and insulin resistance should be determined. The 
measurement of proinsulin level would be a practical 
index suggesting the phenotype of PCOS and potential 
usefulness of metformin treatment. 
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High priority ought to be placed on preventing the 
concurrent occurrence of PCOS and increased BMI. 
Moreover, pharmacological treatment in PCOS 
should be attuned to the phenotype the patient 
presents. We suggest that, due to metabolic disar-
rangements and body fat, we can recognise different 
phenotypes of PCOS. 
This leads to a question: does an obese PCOS 
woman suffer from the same syndrome as a lean PCOS 
woman?
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